GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Matinas BioPharma Holdings MTNB · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.24

+4.20%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Matinas BioPharma Holdings

From its filings with the US Securities and Exchange Commission

SEC filings

Matinas BioPharma Holdings is based in Bedminster, New Jersey and is incorporated in Delaware. Its shares trade on NYSE under the ticker MTNB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2023, it reported revenue of $1.1m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
3 Jun 2014
Employees
21
Head office
1545 ROUTE 206 SOUTH, BEDMINSTER, NJ, 07921
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Jerome JabbourChairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer, since 2013$598,000
  • Ms. Evelyn D'AnIndependent Director
  • Mr. Keith MurphyIndependent Director
  • Mr. Edward NeugeborenIndependent Director
  • Dr. Robin SmithIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
21
Environment
24
Social
14
Governance
25
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Matinas BioPharma's LNC platform technology enables safer drug delivery with lipid-crystal nano-particles.
  • MAT2203 and MAT2501 are key product candidates for anti-infective treatments in development.
  • The company focuses on oral bioavailability and reduced toxicity for existing drugs.

Weaknesses

  • The company has only 21 full-time employees, limiting operational capacity.
  • Matinas BioPharma went public in 2014, indicating limited market presence.
  • The firm's technology relies on lipid-based delivery systems, which may face regulatory hurdles.

Opportunities

  • Expanding the LNC platform to new drug applications in the Health Care sector.
  • MAT2203 targets the anti-fungal market, a growing segment in biotechnology.
  • MAT2501 could address the need for oral aminoglycoside antibiotics in the US market.

Threats

  • Regulatory challenges in the US biotechnology industry may delay product approvals.
  • Competition from established biopharmaceutical firms in the Health Care sector.
  • The limited employee count of 21 may hinder rapid development and scaling.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.